Glenmark has reached a settlement in the antitrust and consumer protection litigations related to generic Zetia® and Vytorin®. The company settled with United Healthcare Services, Inc. for $11 million, payable in two installments. The settlement resolves all outstanding claims related to these litigations. Glenmark denies any liability or illegality in the matter.
Antitrust Lawsuit Settlement
Glenmark has settled with United Healthcare Services, Inc., one of the remaining End-Payor Plaintiffs, for $11 million (USD Dollar Eleven million), payable in two installments. The lawsuits included claims related to both generic Zetia® and Vytorin®.
Background of the Litigation
The litigation arose from antitrust and consumer protection lawsuits concerning generic Zetia®, a drug for treating cholesterol. These lawsuits alleged Glenmark entered an anticompetitive agreement in 2010 to settle patent infringement litigation. Glenmark and Merck have disputed these claims.
Terms of the Resolution
The settlement makes clear that Glenmark denies each and every one of the allegations against it, and the settlement is not on the basis of Glenmark having conceded or admitted any liability or illegality.
Previous Settlements
In 2023, Glenmark settled with three plaintiff groups: the Direct Purchaser Plaintiffs, the Retailer Plaintiffs, and the End-Payor Plaintiffs. In February 2025, Glenmark settled with three plaintiffs, Humana, Centene and Kaiser, for a total of $7 million (US Dollar Seven million).
Full Resolution
With this latest settlement, the generic Zetia® and Vytorin® antitrust and consumer protection litigations are now fully resolved.
Source: BSE
